EUVIMEDEUVIMED entdecken
Crossref

Pharmacokinetics of cycloheximide in rats and evaluation of its effect as a blocker of intestinal lymph formation

Hamdah M Al Nebaihi, Neal M Davies, Dion R Brocks

European Journal of Pharmaceutics and Biopharmaceutics · 2023

DOI: 10.1016/j.ejpb.2023.10.016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2023. Verfasst von Hamdah M Al Nebaihi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Lipids. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cycloheximide (CHX) has been used to reduce the flow of intestinal lymph and as a non-surgical tool to study drug absorption via the intestinal lymphatics. Pharmacokinetic information on the agent, and its relationship to effect and toxicity, have not been examined. The goal of this study was to provide pharmacokinetic data and link it to lymph-blocking and toxicological effects. Jugular-vein cannulated (JVC) adult Sprague-Dawley male rats were administered 0.5 mg/kg CHX by oral, intraperitoneal (ip), and intravenous routes followed by blood draws, and CHX was assayed using LC-MS/MS. Another four JVC rats were given peanut oil (2 mL/kg) without and then with CHX to measure effects on lipid absorption as a surrogate indicator of lymph flow. One-week later plasma biochemistry measures were obtained. The results indicated that CHX had a high clearance and volume of distribution, and oral absolute bioavailability of 0.47 with 0.5 mg/kg. CHX was associated with dose- and route-dependent pharmacokinetics. The relative bioavailability after ip doses was over 3. CHX had low plasma protein binding and minor urinary excretion. Metabolism appeared to be occur by oxidation and glucuronidation. Reductions in plasma lipids (24-40 %) were seen after 2.5 mg/kg orally with signs of inflammation and increased liver enzymes persisting for a week after the dose. CHX was associated with a reduction in lipid absorption after oral doses of 2.5 mg/kg, which seems to justify its use as a non-surgical tool to evaluate the lymphatic pathway of absorption of drugs. However, it also possesses hepatotoxicity, which should be taken into consideration in its use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tandem Mass SpectrometryLipidsRatsMaleAnimalsRats, Sprague-DawleyCycloheximideChromatography, LiquidBiological AvailabilityAdministration, OralIntestinal Absorption

Stichwörter der Autor:innen

BioavailabilityChylomicron inhibitorHepatotoxicityLipid absorption

Substanzen

CycloheximideLipids

Autor:innen und Institutionen

  • Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada.
  • Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada. Electronic address: dbrocks@ualberta.ca.

Zitieren

APA

Al Nebaihi, H. M., Davies, N. M., & Brocks, D. R. (2023). Pharmacokinetics of cycloheximide in rats and evaluation of its effect as a blocker of intestinal lymph formation. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2023.10.016

Vancouver

Al Nebaihi HM, Davies NM, Brocks DR. Pharmacokinetics of cycloheximide in rats and evaluation of its effect as a blocker of intestinal lymph formation. European Journal of Pharmaceutics and Biopharmaceutics. 2023. doi:10.1016/j.ejpb.2023.10.016

BibTeX
@article{AlNebaihi2023,
  author = {Al Nebaihi, Hamdah M and Davies, Neal M and Brocks, Dion R},
  title = {Pharmacokinetics of cycloheximide in rats and evaluation of its effect as a blocker of intestinal lymph formation},
  journal = {European Journal of Pharmaceutics and Biopharmaceutics},
  year = {2023},
  doi = {10.1016/j.ejpb.2023.10.016}
}
Kostenlos starten →